News

Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients

Vienna, Austria – May 5, 2025 Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment Presented at ESTRO 2025. Clinical Study Demonstrates Improved Locoregional Control with Nimorazole in Advanced Head and Neck Cancer....

Lunatus and AFYX Therapeutics A/S Announce Distribution and Sales Collaboration

Hørsholm, Denmark – April 23, 2025 Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX's induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus will distribute,...

Interim Financial Report Q4 2024

In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers in Norway—a trend we expect...
Interim Financial Report Q4 2024

Interim Financial Report Q4 2024

In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers in Norway—a trend we expect...

Two exciting job opportunities at our Hørsholm offices

Two exciting job opportunities at our Hørsholm offices

AFYX Therapeutics is a growing and we have two exciting job opportunities inside Finance & Accounting and Office & Warehouse Administration, respectively. See job posts directly on LInkedIn: Financial Accountant, Copenhagen Area (Hørsholm) - Application due...

OUR LATEST INVESTOR PRESENTATION

Download here:

AFYX Presentation 2024 Investor Non-Confidential

AFYX THERAPEUTICS HQ

Slotsmarken 11, 1.tv.
DK-2970 Hørsholm
Denmark
VAT: 38793594
Phone: +45 7174 7174
info@afyxtx.com

INPHENA NORWAY

Gaustadalléen 21
NO-0349 Oslo
Norway
VAT: 922 558 221
Phone: +47 2396 7174

SIGN UP TO NEWSLETTER